3Z, a Reykjavik, Iceland-based drug discovery company, closed a $2m funding round.
The backers were not disclosed.
The company intends to use the funds to accelerate the finalization of preclinical studies on its lead therapeutic candidates in ADHD and insomnia.
Using its zebrafish screening platform, 3Z has identified both novel and repurposed therapeutics for ADHD and insomnia and the platform allows for cost-effective high-volume screens in vivo.
Currently, the lead therapeutics are being re-assayed in mammalian models, replicating, extending and validating the therapeutic potential of the compounds.
3Z´s CEO Karl Karlsson is a PhD in behavioral neuroscience and professor in Biomedical Engineering at ReykjavikUniversity.
FinSMEs
20/06/2022